Notes_NN
on_PIN
the_DT
Accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
March_NN
2004_CD
31_CD
Acquisitions_NOMZ
continued_VBD
Cascade_NN
Biochem_NN
Limited_NN
acquired_VBD
in_PIN
the_DT
year_NN
ended_VBD
31st_CD
March_NN
2003_CD
On_PIN
17th_JJ
October_NN
2002_CD
the_DT
group_NN
acquired_VBD
Cascade_NN
Biochem_NN
Limited_NN
._.
During_PIN
the_DT
year_NN
the_DT
fair_JJ
values_NN
of_PIN
some_QUAN
of_PIN
the_DT
assets_NN
were_VBD [BYPA]
adjusted_VBN
by_PIN
0.2_CD
million_CD
and_CC
the_DT
estimate_NN
of_PIN
deferred_JJ
consideration_NOMZ
was_VBD [BYPA]
reduced_VBN
by_PIN
2.0_CD
million_CD
._.
Consequently_CONJ
,_,
goodwill_NN
was_VBD [BYPA]
reduced_VBN
by_PIN
1.8_CD
million_CD
._.
VSF_NN
Resin_NN
&_CC
Varnish_NN
Limited_NN
acquired_VBD
in_PIN
the_DT
year_NN
ended_VBD
31st_CD
March_NN
2003_CD
On_PIN
11th_JJ
February_NN
2003_CD
the_DT
group_NN
acquired_VBD
VSF_NN
Resin_NN
&_CC
Varnish_NN
Limited_NN
._.
During_PIN
the_DT
year_NN
0.1_CD
million_CD
of_PIN
deferred_JJ
consideration_NOMZ
was_VBD [PASS]
paid_VBN
and_CC
the_DT
remaining_VBG
deferred_JJ
consideration_NOMZ
was_VBD [BYPA]
reduced_VBN
by_PIN
0.2_CD
million_CD
._.
Consequently_CONJ
,_,
goodwill_NN
was_VBD [BYPA]
reduced_VBN
by_PIN
0.2_CD
million_CD
._.
Pharm-Eco_NN
Laboratories_NN
,_,
Inc._NN
acquired_VBD
in_PIN
the_DT
year_NN
ended_VBD
31st_CD
March_NN
2002_CD
On_PIN
20th_JJ
April_NN
2001_CD
the_DT
group_NN
acquired_VBD
Pharm-Eco_NN
Laboratories_NN
,_,
Inc._NN
._.
During_PIN
the_DT
year_NN
the_DT
remaining_VBG
outstanding_JJ
escrow_NN
claim_NN
of_PIN
0.3_CD
million_CD
was_VBD [PASS]
received_VBN
._.
Avocado_NN
Research_NN
Chemicals_NN
Limited_NN
acquired_VBD
in_PIN
the_DT
year_NN
ended_VBD
31st_CD
March_NN
2002_CD
On_PIN
7th_JJ
February_NN
2002_CD
the_DT
group_NN
acquired_VBD
Avocado_NN
Research_NN
Chemicals_NN
Limited_NN
._.
During_PIN
the_DT
year_NN
loan_NN
notes_NN
of_PIN
1.1_CD
million_CD
were_VBD [PASS]
canceled_VBN
._.
Consequently_CONJ
,_,
goodwill_NN
was_VBD [BYPA]
reduced_VBN
by_PIN
1.1_CD
million_CD
._.
Johnson_NN
Matthey_NN
68_CD
Principal_NN
Subsidiary_NN
Undertakings_GER
and_PHC
Associates_NN
Country_NN
of_PIN
Country_NN
of_PIN
incorporation_NOMZ
incorporation_NOMZ
Europe_NN
Asia_NN
S._NN
A._NN
Johnson_NN
Matthey_NN
N._NN
V._NN
Belgium_NN
Johnson_NN
Matthey_NN
Ceramics_NN
Jiangsu_NN
Co._NN
._.
Ltd._NN
._.
China_NN
Cascade_NN
Biochem_NN
Limited_NN
Eire_NN
Johnson_NN
Matthey_NN
Shanghai_NN
Chemicals_NN
Avocado_NN
Research_NN
Chemicals_NN
Limited_NN
England_NN
Limited_NN
China_NN
Cascade_NN
Biochem_NN
Limited_NN
England_NN
Johnson_NN
Matthey_NN
Hong_NN
Kong_NN
Limited_NN
Hong_NN
Kong_NN
Johnson_NN
Matthey_NN
Fuel_NN
Cells_NN
Limited_NN
82.5_CD
%_NN
England_NN
Johnson_NN
Matthey_NN
India_NN
Private_NN
Limited_NN
90_CD
%_NN
India_NN
Johnson_NN
Matthey_NN
S._NN
A._NN
France_NN
Johnson_NN
Matthey_NN
Chemicals_NN
India_NN
Private_NN
Johnson_NN
Matthey_NN
GmbH_NN
Germany_NN
Limited_NN
India_NN
Johnson_NN
Matthey_NN
Italia_NN
S._NN
p._NN
A._NN
Italy_NN
Johnson_NN
Matthey_NN
Japan_NN
,_,
Inc._NN
._.
USA_NN
Johnson_NN
Matthey_NN
BV_NN
Netherlands_NN
Johnson_NN
Matthey_NN
Sdn_NN
._.
92_CD
%_NN
Malaysia_NN
Johnson_NN
Matthey_NN
Ceramica_NN
Portugal_NN
Lda_NN
Portugal_NN
Johnson_NN
Matthey_NN
Ceramics_NN
Malaysia_NN
Macfarlan_NN
Smith_NN
Limited_NN
Scotland_NN
Sdn_NN
._.
Malaysia_NN
Johnson_NN
Matthey_NN
Ceramics_NN
S._NN
A._NN
Spain_NN
Almiberia_NN
S._NN
A._NN
Spain_NN
Svenska_NN
Emissionsteknik_NN
AB_NN
Sweden_NN
Johnson_NN
Matthey_NN
&_CC
Brandenberger_NN
AG_NN
Switzerland_NN
Africa_NN
Johnson_NN
Matthey_NN
Pty_NN
Limited_NN
South_NN
Africa_NN
Australasia_NN
North_NN
America_NN
AGR_NN
Matthey_NN
20_CD
%_NN
Australia_NN
The_NN
Argent_NN
Insurance_NN
Co._NN
._.
Limited_JJ
Bermuda_NN
Johnson_NN
Matthey_NN
Limited_NN
Canada_NN
South_NN
America_NN
Johnson_NN
Matthey_NN
fide_NN
Mexico_NN
,_,
S._NN
A._NN
fide_NN
C._NN
V._NN
Mexico_NN
Johnson_NN
Matthey_NN
Argentina_NN
S._NN
A._NN
Argentina_NN
Johnson_NN
Matthey_NN
Inc._NN
._.
USA_NN
Johnson_NN
Matthey_NN
Ceramica_NN
Ltda_NN
Brazil_NN
Johnson_NN
Matthey_NN
Catalog_NN
Company_NN
Inc._NN
._.
USA_NN
Johnson_NN
Matthey_NN
Fuel_NN
Cells_NN
,_,
Inc._NN
82.5_CD
%_NN
USA_NN
Pharm-Eco_NN
Laboratories_NN
,_,
Inc._NN
._.
USA_NN
Except_PIN
where_RB
otherwise_CONJ
stated_VBN [PUBV]
,_,
all_QUAN
companies_NN
are_VPRT [SPAU] [PASS]
wholly_RB
owned_VBN
._.
Associate_JJ
see_VPRT [PRIV]
note_NN
14c_JJ
on_PIN
page_NN
57_CD
._.
Investments_NOMZ
held_VBD [PRIV]
directly_RB
by_PIN
parent_NN
company_NN
._.
All_QUAN
the_DT
subsidiary_NN
undertakings_GER
and_PHC
associates_NN
are_VPRT [PASS]
involved_VBN
in_PIN
the_DT
principal_JJ
activities_NOMZ
of_PIN
the_DT
group_NN
._.
